PL3277725T3 - Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma - Google Patents
Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gammaInfo
- Publication number
- PL3277725T3 PL3277725T3 PL16757988T PL16757988T PL3277725T3 PL 3277725 T3 PL3277725 T3 PL 3277725T3 PL 16757988 T PL16757988 T PL 16757988T PL 16757988 T PL16757988 T PL 16757988T PL 3277725 T3 PL3277725 T3 PL 3277725T3
- Authority
- PL
- Poland
- Prior art keywords
- heavy chain
- chain constant
- constant regions
- reduced binding
- gamma receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140350P | 2015-03-30 | 2015-03-30 | |
| PCT/US2016/025051 WO2016161010A2 (en) | 2015-03-30 | 2016-03-30 | Heavy chain constant regions with reduced binding to fc gamma receptors |
| EP16757988.7A EP3277725B1 (en) | 2015-03-30 | 2016-03-30 | Heavy chain constant regions with reduced binding to fc gamma receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3277725T3 true PL3277725T3 (pl) | 2021-06-14 |
Family
ID=56842995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16757988T PL3277725T3 (pl) | 2015-03-30 | 2016-03-30 | Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10556952B2 (pl) |
| EP (1) | EP3277725B1 (pl) |
| JP (1) | JP6773679B2 (pl) |
| AU (1) | AU2016242866B2 (pl) |
| CA (1) | CA2981312C (pl) |
| DK (1) | DK3277725T3 (pl) |
| ES (1) | ES2846748T3 (pl) |
| PL (1) | PL3277725T3 (pl) |
| WO (1) | WO2016161010A2 (pl) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| KR20210126641A (ko) | 2019-02-12 | 2021-10-20 | 리제너론 파아마슈티컬스, 인크. | 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법 |
| AU2020256225B9 (en) | 2019-04-03 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
| WO2020219868A1 (en) | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| BR112022002067A2 (pt) | 2019-08-08 | 2022-06-14 | Regeneron Pharma | Formatos de molécula de ligação ao antígeno |
| US12077603B2 (en) | 2019-08-15 | 2024-09-03 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules for cell targeting and uses thereof |
| MX2022005330A (es) | 2019-11-05 | 2022-05-26 | Regeneron Pharma | Moleculas de union multiespecificas con scfv en el extremo nterminal. |
| WO2021127487A2 (en) * | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| WO2021231447A1 (en) | 2020-05-12 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Novel il10 agonists and methods of use thereof |
| BR112022024662A2 (pt) | 2020-06-03 | 2023-04-04 | Regeneron Pharma | Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2 |
| WO2022060915A1 (en) | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized lanadelumab and administration thereof |
| WO2022060916A1 (en) | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized antibodies for anti-viral therapy |
| WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
| CA3195967A1 (en) | 2020-10-28 | 2022-05-05 | Xu Wang | Vectorized anti-tnf-? antibodies for ocular indications |
| AU2021369833A1 (en) | 2020-10-29 | 2023-06-08 | Regenxbio Inc. | Vectorized tnf-alpha antagonists for ocular indications |
| US20230390418A1 (en) | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| TW202241943A (zh) | 2020-12-29 | 2022-11-01 | 美商銳進科斯生物股份有限公司 | Tau特異性抗體基因療法組合物、方法及其用途 |
| CA3219609A1 (en) | 2021-05-04 | 2022-11-10 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
| CN117597365A (zh) | 2021-05-04 | 2024-02-23 | 再生元制药公司 | 多特异性fgf21受体激动剂及其应用 |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| KR20240046251A (ko) | 2021-08-16 | 2024-04-08 | 리제너론 파아마슈티컬스, 인크. | 신규 il27 수용체 효능제 및 그의 사용 방법 |
| WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| KR20240099460A (ko) | 2021-11-11 | 2024-06-28 | 리제너론 파아마슈티컬스, 인크. | Cd20-pd1 결합 분자 및 이의 사용 방법 |
| WO2023215807A1 (en) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS |
| US20260034246A1 (en) | 2022-05-03 | 2026-02-05 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
| KR20250024872A (ko) | 2022-05-11 | 2025-02-19 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이적 결합 분자 전구단백질 및 이의 용도 |
| CA3257348A1 (en) | 2022-05-27 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | INTERLEUKIN-2 PROPROTEINS AND THEIR USES |
| CA3258187A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | INTERLEUKIN-2 PROPROTEINS AND THEIR USES |
| CN120051483A (zh) | 2022-08-18 | 2025-05-27 | 再生元制药公司 | 干扰素前蛋白及其用途 |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| JP2025534759A (ja) * | 2022-10-18 | 2025-10-17 | クロスポイント セラピューティクス インコーポレイテッド | ヒト抗体ｆｃドメイン変異体及びその用途 |
| EP4634220A2 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses |
| JP2026502547A (ja) | 2023-01-12 | 2026-01-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ＴＧＦβの標的化送達のための組成物及び方法 |
| KR20250148746A (ko) | 2023-01-13 | 2025-10-14 | 리제너론 파아마슈티컬스, 인크. | Fgfr3 결합 분자 및 그의 사용 방법 |
| IL322055A (en) | 2023-01-13 | 2025-09-01 | Regeneron Pharma | IL12 receptor agonists and methods of using them |
| JP2026507123A (ja) | 2023-02-28 | 2026-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔ細胞活性化剤およびその使用方法 |
| EP4709756A1 (en) | 2023-05-10 | 2026-03-18 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| CN121752592A (zh) | 2023-05-12 | 2026-03-27 | 再生元制药公司 | 干扰素受体拮抗剂及其用途 |
| IL325163A (en) | 2023-06-16 | 2026-02-01 | Regeneron Pharma | CD40 × CD40 dual-specific antigen-binding molecules and their application |
| WO2025080538A1 (en) | 2023-10-09 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine |
| US20250114469A1 (en) | 2023-10-09 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE |
| WO2025106469A1 (en) | 2023-11-14 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Engineered heavy chain variable domains and uses thereof |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
| WO2025122614A1 (en) | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025171124A1 (en) | 2024-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025199243A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Trivalent multispecific binding molecules and methods of use thereof |
| WO2025199278A2 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Masked multispecific antigen-binding molecules with cleavable linkers |
| TW202548025A (zh) | 2024-04-08 | 2025-12-16 | 美商銳進科斯生物股份有限公司 | 載體化抗補體抗體與補體劑及其投與 |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| US20250361309A1 (en) | 2024-05-24 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il12 receptor agonists |
| WO2025255452A2 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses thereof |
| WO2025255480A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
| US20260055171A1 (en) | 2024-06-11 | 2026-02-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonists and methods of use thereof |
| WO2026025058A1 (en) | 2024-07-25 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Aav viral particles retargeted to egfr-expressing cancer cells |
| WO2026039325A2 (en) | 2024-08-12 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Modified mtm1 genes and uses thereof |
| WO2026039791A1 (en) | 2024-08-16 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il2 receptor agonists |
| WO2026076013A1 (en) | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted il2 receptor agonists and multispecific t-cell engagers |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| US5057604A (en) | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| SE507922C2 (sv) | 1996-01-31 | 1998-07-27 | Kent Karlsson | Sätt och anordning för frammatning av en doserad mängd sand |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| HUP0100813A3 (en) | 1998-02-25 | 2003-08-28 | Lexigen Pharmaceuticals Corp L | Enhancing the circulating half-life of antibody-based fusion proteins |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| EP2213743A1 (en) * | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| AU2002250293B2 (en) | 2001-03-09 | 2007-10-11 | Arnason, Barry G. Mr | Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| WO2003026490A2 (en) | 2001-09-28 | 2003-04-03 | Elusys Therapeutics, Inc. | Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| US7608260B2 (en) | 2003-01-06 | 2009-10-27 | Medimmune, Llc | Stabilized immunoglobulins |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| GB0312063D0 (en) | 2003-05-27 | 2003-07-02 | Exxonmobil Chem Patents Inc | Catalyst composition II |
| JP2007501021A (ja) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| AU2005335714B2 (en) * | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| AR051836A1 (es) | 2004-11-30 | 2007-02-14 | Centocor Inc | Antagonistas de receptor 3 simil toll metodos y usos |
| US20120189643A1 (en) | 2004-11-30 | 2012-07-26 | Carton Jill M | Toll Like Receptor 3 Antagonists, Methods and Uses |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| KR20080073293A (ko) | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| SG10201400426XA (en) | 2006-01-12 | 2014-07-30 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| JP4294082B2 (ja) | 2006-03-23 | 2009-07-08 | 協和発酵キリン株式会社 | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
| MY149079A (en) | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| ES2623925T3 (es) | 2007-05-30 | 2017-07-12 | Postech Academy-Industry- Foundation | Proteínas de fusión de inmunoglobulina |
| JP5511654B2 (ja) | 2007-05-31 | 2014-06-04 | ゲンマブ エー／エス | 分子操作により得られた組換え非グリコシル化一価半抗体 |
| JP6071165B2 (ja) | 2007-05-31 | 2017-02-01 | ゲンマブ エー／エス | 安定なＩｇＧ４抗体 |
| US20110077383A1 (en) | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| MX2010003329A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de il-6. |
| RU2010138612A (ru) | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR |
| EP2356154A4 (en) | 2008-11-06 | 2012-12-19 | Alexion Pharma Inc | DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF |
| PL2918604T3 (pl) | 2008-11-07 | 2018-05-30 | Amgen Research (Munich) Gmbh | Leczenie pediatrycznej ostrej białaczki limfoblastycznej |
| AR074438A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal |
| AU2009324092A1 (en) | 2008-12-03 | 2011-06-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| US8961967B2 (en) | 2009-11-30 | 2015-02-24 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| CN102167741B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗TNF-α单克隆抗体、其制备方法及用途 |
| WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| JP2013528357A (ja) | 2010-03-29 | 2013-07-11 | ザイムワークス，インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
| BR112012027917A2 (pt) | 2010-04-30 | 2017-11-28 | Alexion Pharma Inc | anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| EP2585828A4 (en) | 2010-06-25 | 2014-03-12 | Glaxo Group Ltd | METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| KR101871008B1 (ko) | 2010-09-16 | 2018-06-25 | 발리오팜 아게 | 항-huTNFR1 항체 |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| ES2623912T3 (es) | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| WO2013026839A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| WO2013112986A1 (en) | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| EP2825553B1 (en) | 2012-03-14 | 2018-07-25 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| MX2014014891A (es) | 2012-06-05 | 2015-06-17 | Regeneron Pharma | Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun. |
| AU2013289883B2 (en) | 2012-07-13 | 2018-11-01 | Zymeworks Bc Inc. | Bispecific asymmetric heterodimers comprising anti-CD3 constructs |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| HUE042040T2 (hu) | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| US9714291B2 (en) | 2012-10-05 | 2017-07-25 | Kyowa Hakko Kirin Co., Ltd | Heterodimer protein composition |
| RU2015117393A (ru) | 2012-10-08 | 2016-12-10 | Роше Гликарт Аг | Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| WO2015006749A2 (en) | 2013-07-12 | 2015-01-15 | Zymeworks Inc. | Bispecific cd3 and cd19 antigen binding contructs |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| EP3083696B1 (en) | 2013-12-20 | 2018-02-14 | F.Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| GB201506407D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| LT3394103T (lt) | 2015-12-22 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| TW202504917A (zh) | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| KR20230047214A (ko) | 2019-07-26 | 2023-04-06 | 벨로3디, 인크. | 3차원 물체 형상화에 대한 품질 보증 |
| US12077603B2 (en) | 2019-08-15 | 2024-09-03 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules for cell targeting and uses thereof |
-
2016
- 2016-03-30 WO PCT/US2016/025051 patent/WO2016161010A2/en not_active Ceased
- 2016-03-30 CA CA2981312A patent/CA2981312C/en active Active
- 2016-03-30 JP JP2017551033A patent/JP6773679B2/ja active Active
- 2016-03-30 US US15/562,881 patent/US10556952B2/en active Active
- 2016-03-30 ES ES16757988T patent/ES2846748T3/es active Active
- 2016-03-30 PL PL16757988T patent/PL3277725T3/pl unknown
- 2016-03-30 DK DK16757988.7T patent/DK3277725T3/da active
- 2016-03-30 EP EP16757988.7A patent/EP3277725B1/en active Active
- 2016-03-30 AU AU2016242866A patent/AU2016242866B2/en active Active
-
2019
- 2019-12-19 US US16/720,623 patent/US11518807B2/en active Active
-
2022
- 2022-10-06 US US17/961,442 patent/US12509516B2/en active Active
-
2025
- 2025-11-24 US US19/398,850 patent/US20260085116A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3277725A2 (en) | 2018-02-07 |
| US20200109203A1 (en) | 2020-04-09 |
| US11518807B2 (en) | 2022-12-06 |
| JP2018512420A (ja) | 2018-05-17 |
| WO2016161010A2 (en) | 2016-10-06 |
| US20230287117A1 (en) | 2023-09-14 |
| US20180282411A1 (en) | 2018-10-04 |
| US12509516B2 (en) | 2025-12-30 |
| EP3277725B1 (en) | 2020-11-25 |
| CA2981312C (en) | 2023-09-26 |
| DK3277725T3 (da) | 2021-01-11 |
| JP6773679B2 (ja) | 2020-10-21 |
| US10556952B2 (en) | 2020-02-11 |
| US20260085116A1 (en) | 2026-03-26 |
| ES2846748T3 (es) | 2021-07-29 |
| AU2016242866A1 (en) | 2017-10-26 |
| CA2981312A1 (en) | 2016-10-06 |
| AU2016242866B2 (en) | 2021-06-03 |
| HK1250039A1 (zh) | 2018-11-23 |
| WO2016161010A3 (en) | 2016-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3277725T3 (pl) | Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma | |
| IL259173A (en) | Ctla4 binders | |
| IL263266A (en) | Anti hla-g specific antibodies | |
| IL271194A (en) | Anti-bcma heavy chain-only antibodies | |
| IL262128A (en) | T cell receptors | |
| IL262124A (en) | T cell receptors | |
| IL262146A (en) | T cell receptors | |
| PL3328894T3 (pl) | Przeciwciała dla il2rbeta/wspólnego łańcucha gamma | |
| IL251524A0 (en) | T cell receptors | |
| HUE051496T2 (hu) | TL1A-hoz specifikusan kötõdõ ellenanyagok | |
| KR102355950B9 (ko) | Tigit에 대한 항체 | |
| HUE059159T2 (hu) | T-sejt-receptorok | |
| PL3126383T3 (pl) | Zmodyfikowany łańcuch J | |
| BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
| HUE048667T2 (hu) | AXL-hez kötõdõ ellenanyagok | |
| LT3149345T (lt) | Būdas dviem objektams sujungti | |
| EP4230711C0 (en) | BRIQUETTES | |
| LT3433270T (lt) | T ląstelių receptoriai | |
| EP3369944A4 (en) | HYDRAULIC DEVICE | |
| DK3145536T3 (da) | Modificeret tyrosinammoniaklyase | |
| HUE047455T2 (hu) | HPA-1A elleni antitestek | |
| NO344137B1 (no) | Selvjusterende hivkompensator | |
| DK3259407T3 (da) | Hydraulisk indretning | |
| FR3020302B3 (fr) | Tronconneuse | |
| ES1141490Y (es) | Mochila |